Workshop: Options for therapy in ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 3 SUPPL., 2003, Pages

  Herzog, Thomas J ^a   Holloway, Robert W ^b   Stuart, Gavin C E ^c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Ovarian cancer; Sequencing; Topotecan

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; PACLITAXEL; PLATINUM; TAMOXIFEN; TOPOTECAN;

ABDOMINAL HYSTERECTOMY; ANEMIA; ASIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHRONOSEQUENCE; CHRONOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENCAPSULATION; EUROPE; HUMAN; LEUKOPENIA; LONG TERM EXPOSURE; LOW DRUG DOSE; NEUTROPENIA; ONCOLOGY; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SEPSIS; SHORT COURSE THERAPY; SIDE EFFECT; SYMPTOM; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

EID: 0042232332     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00473-6     Document Type: Conference Paper

References (28)

1. Armstrong D.K. Relapsed ovarian cancer challenges and management strategies for a chronic disease . Oncologist. 7:(suppl 5):2002;20-28.
2. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
3. Armstrong D., O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 3:1998;4-10.
4. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003;90(3):S39-43.
5. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 14:1996;1552-1557.
6. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer a National Cancer Institute of Canada Clinical Trials Group study . J Clin Oncol. 16:1998;2233-2237.
7. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;1062-1067.
8. National Institute for Clinical Excellence. Guidance on the use of topotecan for the treatment of advanced ovarian cancer. NICE Technology Appraisal Guidance No. 28, August 2001.
9. National Institute for Clinical Excellence. Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer. NICE Technology Appraisal Guidance No. 45, July
10. Mehta R.S., Bornstein R., Yu I.-R., Parker R.J., McClaren M.C.E., Nguyen K.P., Fruehauf J.P. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat. 66:2001;225-237.
11. Holloway R.W., Mehta R.S., Finkler N., Parker R.J., Fruehauf J.P. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 87:2002;8-16.
12. Bergman A.M., Pinedo H.M., Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Update. 5:2002;19-33.
13. Staker B.J., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B. Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA. 26:2002;15387-15392.
14. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer implications for patient treatment and the design of phase II trials . Br J Cancer. 59:1989;650-653.
15. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
16. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J.L. Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
17. Ledermann JA, on behalf of ICON and AGO Collaborators. Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR2.2). Proc Am Soc Clin Oncol 2003;22:A1794.
18. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 16:1998;405-410.
19. Rodriguez M., Rose P.G. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 83:2001;257-262.
20. Brown J.V., Peters W.A., Rettenmaier M.A., Graham C.L., Smith M.R., Drescher C.W., et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 88:2003;136-140.
21. Gore M., Rustin G., Schüller J., Lane S.R., Hearn S., Beckman R.A., et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer. 84:2001;1043-1046.
22. Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 17:1999;2553-2561.
23. Morris R., Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist. 7:(suppl 5):2002;29-35.
24. Homesley H., Benigno B., Williams J., Vaccarello L. A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol Oncol. 87:2002;171-177.
25. Frasci G., Panza N., Comella P., Carteni G., Guida T., Nicolella G.P., et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients a dose-finding study . Ann Oncol. 10:1999;355-358.
26. Mobus V., Pfaff P.N., Volm T., Kreienberg R., Kaubitzsch S. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res. 21:2001;3551-3556.
27. González-Beca R., Arranz J.A., Borrega P., Bolaños M., Velasco A., Pérez M., et al. Weekly paclitaxel and carboplatin followed by topotecan (TCTp) as first-line therapy for patients with advanced epithelial ovarian cancer (AOC) suboptimally debulked. Preliminary results. Proc Am Soc Clin Oncol. 20:2001;A856.
28. Pfisterer J., Lortholary A., Kimmig R., Weber B., Du Bois A., Bourgeois H., et al. Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a gynecologic cancer Intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol. 22:2003;A1793.